These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 36113258

  • 1. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, Jiang Z, Li Y, Han J, Gan W, Yang F, Zhang X, Liu Y, Sun C, He J, Liu M, Zuo D, Zhu W, Wu Y.
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [Abstract] [Full Text] [Related]

  • 2. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J, Zhang Y, Tang N, Lu Y, Guo P, Huang Z.
    Bioorg Med Chem; 2021 Feb 15; 32():115997. PubMed ID: 33440319
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S, Luo L, Sun X, Yang Y, Guo Q, Jiang Z, Wu Y.
    Bioorg Med Chem; 2023 Jan 15; 78():117133. PubMed ID: 36599263
    [Abstract] [Full Text] [Related]

  • 4. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C, Qiu S, Liu P, Ge Y, Gao X.
    J Ethnopharmacol; 2018 Jan 30; 211():89-100. PubMed ID: 28962890
    [Abstract] [Full Text] [Related]

  • 5. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    Neoplasia; 2014 Jan 30; 16(1):43-72. PubMed ID: 24563619
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.
    Wang LL, Huang WW, Huang J, Huang RF, Li NN, Hong Y, Chen ML, Wu F, Liu J.
    Kaohsiung J Med Sci; 2020 Aug 30; 36(8):581-591. PubMed ID: 32311203
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y, Hu S, Chen Y, Zhang X, Gao H, Tian J, Chen J.
    Phytomedicine; 2023 Sep 30; 118():154924. PubMed ID: 37393829
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, Miao QF.
    Mil Med Res; 2021 Dec 09; 8(1):63. PubMed ID: 34879870
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE, Yang L, Chen K, Wang Y, Liu YR, Pan SL, Gaur S, Hu S, Yen Y.
    Oncotarget; 2015 May 10; 6(13):11061-73. PubMed ID: 25857298
    [Abstract] [Full Text] [Related]

  • 14. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, Liao H, Xu L, Wang D, Guo X.
    FEBS Open Bio; 2020 Apr 10; 10(4):535-545. PubMed ID: 32027103
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X, Zhang B, Luo L, Yang Y, He B, Zhang Q, Wang L, Xu S, Zheng P, Zhu W.
    Bioorg Chem; 2022 Dec 10; 129():106157. PubMed ID: 36209563
    [Abstract] [Full Text] [Related]

  • 16. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL, Ma WJ, Chen S, Wu XZ, Zhang HR, Zhang JH.
    Zhonghua Zhong Liu Za Zhi; 2016 Aug 10; 38(8):578-88. PubMed ID: 27531477
    [Abstract] [Full Text] [Related]

  • 17. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.
    Breast Cancer Res; 2014 Aug 08; 16(4):406. PubMed ID: 25103565
    [Abstract] [Full Text] [Related]

  • 18. A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer.
    Luo L, Sun X, Yang Y, Xia L, Wang S, Fu Y, Zhu Y, Xu S, Zhu W.
    Int J Mol Sci; 2023 Oct 01; 24(19):. PubMed ID: 37834269
    [Abstract] [Full Text] [Related]

  • 19. Chamomile Essential Oil: Chemical Constituents and Antitumor Activity in MDA-MB-231 Cells through PI3K/Akt/mTOR Signaling Pathway.
    An Z, Feng X, Sun M, Wang Y, Wang H, Gong Y.
    Chem Biodivers; 2023 Apr 01; 20(4):e202200523. PubMed ID: 36941224
    [Abstract] [Full Text] [Related]

  • 20. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L, Chen X, Fu S, Yu W, Li C, Wang T, Lo HW, Lin J.
    Breast Cancer Res Treat; 2020 May 01; 181(1):31-41. PubMed ID: 32240456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.